Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA)
CUSIP: 92337R101
Q2 2022 13F Holders as of 30 Jun 2022
- Type / Class
- Equity / Class A Common Stock, par value $0.001 per share
- Shares outstanding
- 72,325,000
- Total 13F shares
- 20,391,008
- Share change
- +908,701
- Total reported value
- $277,615,038
- Price per share
- $13.61
- Number of holders
- 49
- Value change
- +$7,846,841
- Number of buys
- 25
- Number of sells
- 14
Quarterly Holders Quick Answers
What is CUSIP 92337R101?
CUSIP 92337R101 identifies VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Related Filing Research
- Latest 13F filings for newly reported positions.
- Latest Schedule 13D/13G reports for ownership changes outside 13F cadence.
- Latest 10-Q/10-K reports for financial context tied to this issuer.
- Recent insider transactions for executive and insider activity.
- SEC investors directory and top value investors for manager drilldown.
- Back to full security ownership history.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 92337R101:
Top shareholders of VERA - Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| FMR LLC |
13F
|
Company |
5.5%
|
4,012,030
|
$94,243,000 | — | 31 Mar 2022 | |
| Sofinnova Investments, Inc. |
13F
|
Company |
4.4%
|
3,181,442
|
$74,732,000 | — | 31 Mar 2022 | |
| Abingworth LLP |
13F
3/4/5
|
Company · 10%+ Owner |
4.1%
|
2,960,231
|
$69,299,000 | — | 31 Mar 2022 | |
| Emster Kurt von |
3/4/5
|
Director |
—
mixed-class rows
|
2,987,984
mixed-class rows
|
$53,605,062 | — | 17 May 2021 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
2.9%
|
2,089,520
|
$49,083,000 | — | 31 Mar 2022 | |
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
2.7%
|
1,966,084
|
$46,183,000 | — | 31 Mar 2022 | |
| BlackRock Finance, Inc. |
13F
|
Company |
0.94%
|
679,675
|
$15,965,000 | — | 31 Mar 2022 | |
| Vivo Capital, LLC |
13F
|
Company |
0.92%
|
666,666
|
$15,660,000 | — | 31 Mar 2022 | |
| VANGUARD GROUP INC |
13F
|
Company |
0.85%
|
618,003
|
$14,517,000 | — | 31 Mar 2022 | |
| Octagon Capital Advisors LP |
13F
|
Company |
0.8%
|
575,000
|
$13,507,000 | — | 31 Mar 2022 | |
| Kynam Capital Management, LP |
13F
|
Company |
0.69%
|
502,328
|
$11,800,000 | — | 31 Mar 2022 | |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC |
13F
|
Company |
0.26%
|
190,749
|
$11,613,000 | — | 31 Mar 2022 | |
| Logos Global Management LP |
13F
|
Company |
0.53%
|
385,000
|
$9,044,000 | — | 31 Mar 2022 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
0.46%
|
333,333
|
$7,830,000 | — | 31 Mar 2022 | |
| Alphabet Inc. |
13F
|
Company |
0.42%
|
301,580
|
$7,084,000 | — | 31 Mar 2022 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
0.28%
|
202,547
|
$4,757,000 | — | 31 Mar 2022 | |
| STATE STREET CORP |
13F
|
Company |
0.23%
|
168,757
|
$3,964,000 | — | 31 Mar 2022 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.21%
|
149,601
|
$3,514,000 | — | 31 Mar 2022 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.18%
|
133,500
|
$3,136,000 | — | 31 Mar 2022 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.15%
|
109,407
|
$2,570,000 | — | 31 Mar 2022 | |
| Maven Securities LTD |
13F
|
Company |
0.09%
|
64,240
|
$1,509,000 | — | 31 Mar 2022 | |
| Polar Asset Management Partners Inc. |
13F
|
Company |
0.08%
|
60,000
|
$1,409,000 | — | 31 Mar 2022 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.07%
|
48,836
|
$1,146,000 | — | 31 Mar 2022 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.07%
|
53,623
|
$1,143,000 | — | 31 Mar 2022 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.05%
|
34,743
|
$817,000 | — | 31 Mar 2022 | |
| MORGAN STANLEY |
13F
|
Company |
0.03%
|
18,518
|
$435,000 | — | 31 Mar 2022 | |
| Raymond James Financial Services Advisors, Inc. |
13F
|
Company |
0.02%
|
17,828
|
$419,000 | — | 31 Mar 2022 | |
| Gyon Technologies Capital Management, LP |
13F
|
Company |
0.02%
|
16,961
|
$398,000 | — | 31 Mar 2022 | |
| CARNEGIE MELLON UNIVERSITY |
13F
|
Company |
0.02%
|
16,060
|
$377,000 | — | 31 Mar 2022 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.02%
|
15,604
|
$367,000 | — | 31 Mar 2022 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.02%
|
13,277
|
$312,000 | — | 31 Mar 2022 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.02%
|
10,983
|
$258,000 | — | 31 Mar 2022 | |
| CITIGROUP INC |
13F
|
Company |
0.02%
|
10,895
|
$256,000 | — | 31 Mar 2022 | |
| RHUMBLINE ADVISERS |
13F
|
Company |
0.01%
|
10,385
|
$244,000 | — | 31 Mar 2022 | |
| CAMBRIDGE TRUST CO |
13F
|
Company |
0.01%
|
9,887
|
$232,000 | — | 31 Mar 2022 | |
| MetLife Investment Management, LLC |
13F
|
Company |
0.01%
|
8,881
|
$208,615 | — | 31 Mar 2022 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.01%
|
8,104
|
$191,000 | — | 31 Mar 2022 | |
| AMERICAN INTERNATIONAL GROUP, INC. |
13F
|
Company |
0.01%
|
6,794
|
$160,000 | — | 31 Mar 2022 | |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM |
13F
|
Company |
0.01%
|
5,850
|
$137,000 | — | 31 Mar 2022 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0%
|
2,955
|
$69,000 | — | 31 Mar 2022 | |
| BARCLAYS PLC |
13F
|
Company |
0%
|
2,222
|
$53,000 | — | 31 Mar 2022 | |
| UBS Group AG |
13F
|
Company |
0%
|
2,009
|
$47,000 | — | 31 Mar 2022 | |
| STRS OHIO |
13F
|
Company |
0%
|
1,600
|
$37,000 | — | 31 Mar 2022 | |
| AMALGAMATED BANK |
13F
|
Company |
0%
|
1,438
|
$34,000 | — | 31 Mar 2022 | |
| Amalgamated Financial Corp. |
13F
|
Company |
0%
|
1,438
|
$34,000 | — | 31 Mar 2022 | |
| ROYAL BANK OF CANADA |
13F
|
Company |
0%
|
1,341
|
$32,000 | — | 31 Mar 2022 | |
| Legal & General Group Plc |
13F
|
Company |
0%
|
1,307
|
$31,000 | — | 31 Mar 2022 | |
| Ameritas Investment Partners, Inc. |
13F
|
Company |
0%
|
1,061
|
$25,000 | — | 31 Mar 2022 | |
| METROPOLITAN LIFE INSURANCE CO/NY |
13F
|
Company |
0%
|
1,041
|
$24,453 | — | 31 Mar 2022 | |
| US BANCORP \DE\ |
13F
|
Company |
0%
|
1,000
|
$23,000 | — | 31 Mar 2022 |
Institutional Holders of Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) as of Q2 2022
As of 30 Jun 2022,
Vera Therapeutics, Inc. - Class A Common Stock, par value $0.001 per share (VERA) was held by
49 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,391,008 shares.
The largest 10 holders included
FMR LLC, Sofinnova Investments, Inc., Abingworth LLP, CITADEL ADVISORS LLC, RA CAPITAL MANAGEMENT, L.P., Kynam Capital Management, LP, BlackRock Inc., VANGUARD GROUP INC, Vivo Capital, LLC, and Octagon Capital Advisors LP.
This page lists
49
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2022 vs Q1 2022 Across Filers
Q1 2022 holders
49
Q2 2022 holders
49
Holder diff
0
| Investor | Q1 2022 Shares | Q2 2022 Shares | Share Diff | Share Chg % | Q1 2022 Value $ | Q2 2022 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.